LCN2 and breast cancer: Results in Table 4 documented that there was significant difference between the mean levels of Omenti-1 (98.4 ± 8.2 ng/ml) and NGAL (117.6 ± 15.7 ng/ml) in healthy control and breast cancer patients (316.5 ± 293.6 ng/ml and 488.5 ± 388 ng/ml), respectively (p < 0.001) (Figures 1 and 2).